Company intelligence / Profile preview
Harras Pharma Curarina
München, Bavaria, Germanyharraspharma.de ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has developed and commercialized several herbal-based medicinal products with proven efficacy and safety. Traumaplant®, a comfrey-based pain cream, has been validated in multiple clinical studies for blunt injuries. Sucontral® D for diabetes management and Sensicutan® for skin conditions are also approved and marketed internationally.
- Therapeutic areas
- DermatologyEndocrinologyInfectious DiseasesOther
- Modalities
- Herbal extract therapySmall molecule
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Outlicensing partners in various countries including USA, Canada, Austria, Switzerland, Peru, Slovakia, Czech Republic, England.
Beyond the preview
Go deeper on Harras Pharma Curarina.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Harras Pharma Curarina.